GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Baxter International Inc (NYSE:BAX) » Definitions » Cash Conversion Cycle

Baxter International (Baxter International) Cash Conversion Cycle : 133.27 (As of Mar. 2024)


View and export this data going back to 1961. Start your Free Trial

What is Baxter International Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Baxter International's Days Sales Outstanding for the three months ended in Mar. 2024 was 66.19.
Baxter International's Days Inventory for the three months ended in Mar. 2024 was 120.26.
Baxter International's Days Payable for the three months ended in Mar. 2024 was 53.18.
Therefore, Baxter International's Cash Conversion Cycle (CCC) for the three months ended in Mar. 2024 was 133.27.


Baxter International Cash Conversion Cycle Historical Data

The historical data trend for Baxter International's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Baxter International Cash Conversion Cycle Chart

Baxter International Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only Premium Member Only 99.55 103.10 120.78 119.09 123.29

Baxter International Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 131.72 119.86 119.43 121.79 133.27

Competitive Comparison of Baxter International's Cash Conversion Cycle

For the Medical Instruments & Supplies subindustry, Baxter International's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Baxter International's Cash Conversion Cycle Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Baxter International's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Baxter International's Cash Conversion Cycle falls into.



Baxter International Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Baxter International's Cash Conversion Cycle for the fiscal year that ended in Dec. 2023 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=64.82+102.08-43.61
=123.29

Baxter International's Cash Conversion Cycle for the quarter that ended in Mar. 2024 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=66.19+120.26-53.18
=133.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Baxter International  (NYSE:BAX) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Baxter International Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Baxter International's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Baxter International (Baxter International) Business Description

Address
One Baxter Parkway, Deerfield, IL, USA, 60015
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment, including hospital beds, to the portfolio, although about half of Hillrom's revenue comes from more digitally connected offerings like its smart beds and Voalte medical communications app. From its legacy operations, Baxter offers tools to help patients with acute and chronic kidney failure, which it plans to spin off by mid-2024. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents.
Executives
Joel T. Grade officer: EVP, Chief Financial Officer SYSCO CORPORATION, 1390 ENCLAVE PARKWAY, HOUSTON TX 77077
Stephen H Rusckowski director C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Ampofo William A. Ii director ONE BAXTER PARKWAY, DEERFIELD IL 60015
Christopher A. Toth officer: EVP, Group Pres, Kidney Care 1252 COOLIDGE AVE., SAN JOSE CA 95125
Stroucken Albert P L director BAXTER INTERNATIONAL INC., ONE BAXTER PARKWAY, DEERFIELD IL 60015
Reaz Rasul officer: EVP, Group Pres, Healthcare ONE BAXTER PARKWAY, DEERFIELD IL 60015
Alok Sonig officer: EVP, Group President, Pharm ONE BAXTER PARKWAY, DEERFIELD IL 60015
Heather Knight officer: EVP, Group Pres, Medical ONE BAXTER PARKWAY, DEERFIELD IL 60015
Jacqueline Kunzler officer: SVP, Chief Quality Officer ONE BAXTER PARKWAY, DEERFIELD IL 60015
Jeanne K Mason officer: CVP, Human Resources ONE BAXTER PARKWAY, DEERFIELD IL 60015
Steven Flynn officer: SVP, President, APAC ONE BAXTER PARKWAY, DEERFIELD IL 60015
Peter M Wilver director
David Brent Shafer director 2800 ROCKCREEK PARKWAY, NORTH KANSAS CITY MO 64117
Amy Mcbride Wendell director COVIDIEN LTD., 15 HAMPSHIRE STREET, MANSFIELD MA 02048
Cathy R Smith director TARGET CORPORATION, 1000 NICOLLET MALL, TPS-3155, MINNEAPOLIS MN 55403